Trial reportParasitology research2015
Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs.
Trial report in Parasitology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Article
- Unveiling Dirofilaria Asiatica infection: first clinical insights and treatment challenges for this feline zoonotic parasitosis.Veterinary research communications · 2025Article
- Case report of a triple vector-borne infection in a dog: co-infection with Anaplasma phagocytophilum, Babesia spp., and Dirofilaria repens in North-Eastern Poland.BMC veterinary research · 2025Article
- Zoonotic filariasis and its public health significance: a comprehensive literature review.Frontiers in microbiology · 2025Review
- A Rare Case of Dirofilariasis in the Genian Region.Diagnostics (Basel, Switzerland) · 2024Article
- Occurrence of Dirofilaria repens in wild carnivores in Poland.Parasitology research · 2023Article
- Efficacy of oral, topical and extended-release injectable formulations of moxidectin combined with doxycycline in Dirofilaria immitis naturally infected dogs.Parasites & vectors · 2023Article
- The long-distance relationship betweenFrontiers in veterinary science · 2023Review
- Estimated specific antibody-based true sero-prevalences of canine filariosis in dogs in Central Europe and the UK.Parasitology research · 2022Article
- Selection of new diagnostic markers for Dirofilaria repens infections with the use of phage display technology.Scientific reports · 2022Article
- A case of inguinal hernia associated with atypical Dirofilaria repens infection in a dog.Parasites & vectors · 2021Article
- New insights into the biology, diagnosis and immune response toVeterinary parasitology: X · 2020Article
- Current trends in canine dirofilariosis in Austria-do we face a pre-endemic status?Parasitology research · 2020Article
- Case Studies of Severe Microfilaremia in Four Dogs Naturally Infected WithFrontiers in veterinary science · 2020Article
- Recent advances on Dirofilaria repens in dogs and humans in Europe.Parasites & vectors · 2018Review
- Subcutaneous dirofilariosis (Dirofilaria repens): an infection spreading throughout the old world.Parasites & vectors · 2017Review
- The Mitochondrial Genomes of the Zoonotic Canine Filarial Parasites Dirofilaria (Nochtiella) repens and Candidatus Dirofilaria (Nochtiella) hongkongensis Provide Evidence for Presence of Cryptic Species.PLoS neglected tropical diseases · 2016Article
- The prevalence of Dirofilaria repens in cats, healthy dogs and dogs with concurrent babesiosis in an expansion zone in central Europe.BMC veterinary research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the efficacy of imidacloprid 10 %/moxidectin 2.5 % (w/v) spot-on (Advocate®/Advantage® Multi, Bayer) against adult Dirofilaria repens in a blinded, placebo-controlled randomised laboratory study. Twenty-four Beagle dogs were experimentally infected with approximately 75 infective D. repens larvae each on study day (SD) 0. Treatment was initiated on SD 228 after patency had been confirmed in 21 dogs, using a modified Knott Test. Eleven dogs received monthly treatments with imidacloprid/moxidectin at the minimum therapeutic dose (10 mg/kg imidacloprid and 2.5 mg/kg moxidectin) for six consecutive months and 12 control dogs were treated with a placebo formulation. Approximately one month after the last treatment, all dogs were euthanised and necropsied for the detection of D. repens worms. Eleven control dogs harboured live adult D. repens (range 2-11, geometric mean 5.44). Eight of 11 imidacloprid/moxidectin-treated dogs were free of live worms. The live worm count was reduced by 96.2 % (range 0-1, geometric mean 0.21). The majority of dead worms were encapsulated and degenerated. After the first treatment, Knott Tests were negative in all imidacloprid/moxidectin-treated dogs and this status was maintained in 10 dogs until study end. One dog showed a low microfilariae count (1 and 4/mL) on four occasions but was also negative before necropsy. The treatment was well tolerated by all study animals. It is concluded that six consecutive monthly treatments with imidacloprid/moxidectin spot-on are effective and safe against adult D. repens and provide an option for preventing the further spread of this zoonotic parasite.
Indexed as
Identifiers
26152414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.